统计剂对血液凝固的影响:一篇评论
Carmine Siniscalchi1, Manuela Basaglia2, Michele Riva2
1Angiology Unit, Department of Internal Medicine, Parma University Hospital, 43121 Parma, Italy.
Cells
|December 9, 2023
概括
用于心血管疾病的他类药物显示出潜在的抗凝固和抗血小板作用. 这些特性可能有助于减少静脉血栓塞栓症 (VTE) 和相关死亡,尽管需要进一步研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 心血管医学 心血管医学
背景情况:
- 类他类药物是广泛处方的降脂药物,其向胆固醇生物合成.
- 它们在静脉血栓栓塞 (VTE) 预防和管理中的作用需要进一步阐明.
- 现有数据表明,他类药物可能会影响血液凝结和血小板功能.
研究的目的:
- 审查关于他类药物对凝血系统的直接干扰的生物证据和实验数据.
- 探索他类药物的潜在抗凝和抗血小板机制.
- 评估这些机制对VTE预防的影响.
主要方法:
- 关于他类药物对凝血因子和途径的影响的实验研究和临床数据的综述.
- 对他类药物对组织因子,血栓模块素,血栓生成和纤维蛋白分裂的影响的分析.
- 检查关于他类药物诱导的抗血小板作用的证据.
主要成果:
- 类他类药物通过降低组织因子和增强血栓模块素表达来表现出抗凝固作用,减少血栓生成.
- 它们会损害纤维素素分裂,并减少V和XIII因子的激活.
- 类药物表现出抗血小板作用,抑制血小板激活,粘附和聚合.
结论:
- 类固醇诱导的抗凝剂和抗血小板作用为其在VTE预防中的潜在作用提供了生物学基础.
- 这些机制可能部分解释了观察到的VTE和相关死亡率的减少.
- 虽然预防动脉血栓形成的证据是强有力的,但他类药物在静脉瘤中的作用需要进一步研究.
关键词:
这是一个V/Va因子.在XIII/XIIIa因子上.纤维素纤维素是一种纤维素.纤维素原体是一种纤维原体.蛋白质C通路中的蛋白质C斯塔丁是一个国家.血栓激素 血栓激素 是一种组织因子是组织因子.组织因子通路抑制剂静脉血栓塞栓症是一种静脉血栓塞栓.更多相关视频
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.3K
09:41Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
Published on: March 5, 2020
9.2K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
667
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
164
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
164
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
01:16Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K